摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-Tert-butyl-2-chloroquinoline | 1251922-47-0

中文名称
——
中文别名
——
英文名称
6-Tert-butyl-2-chloroquinoline
英文别名
——
6-Tert-butyl-2-chloroquinoline化学式
CAS
1251922-47-0
化学式
C13H14ClN
mdl
——
分子量
219.71
InChiKey
UIFPDRONYYVOCN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    12.9
  • 氢给体数:
    0
  • 氢受体数:
    1

文献信息

  • Monoacylglycerol Lipase Modulators
    申请人:Janssen Pharmaceutica NV
    公开号:US20200102311A1
    公开(公告)日:2020-04-02
    Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein R 2 , R 3 R 4 , R 5 and R 6 are defined herein.
    桥接化合物,其结构式为(I)和(II),包含它们的药物组合物,制造它们的方法,以及使用它们的方法,包括用于治疗与MGL调节相关的疾病状态、障碍和状况的方法,如与疼痛、精神障碍、神经障碍(包括但不限于重性抑郁障碍、难治性抑郁、焦虑性抑郁、双相情感障碍)、癌症和眼科疾病相关的方法。 其中R2、R3、R4、R5和R6的定义如下。
  • Kinase antagonists
    申请人:Knight A. Zachary
    公开号:US20070293516A1
    公开(公告)日:2007-12-20
    The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tryosine kinase, PI3Kinase and mTOR, or PI3Kinase, mTOR and tryosine kinase.
    本发明提供了一种新型化合物,它们是 PI3 激酶、PI3 激酶和酪氨酸激酶、PI3 激酶和 mTOR,或者 PI3 激酶、mTOR 和酪氨酸激酶的拮抗剂。
  • METHODS AND COMPOSITIONS FOR TREATMENT OF OPHTHALMIC CONDITIONS
    申请人:Wilson Troy Edward
    公开号:US20110269779A1
    公开(公告)日:2011-11-03
    The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating signal transduction by certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PB kinase in an ocular tissue. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.
    本发明提供了能够调节特定蛋白激酶(如mTor、酪氨酸激酶和/或脂质激酶如PB激酶)在眼组织中的信号传导的化学实体或化合物以及其制药组合物。本发明还提供了利用这些组合物调节这些激酶中的一个或多个的活性的方法,特别是用于治疗应用。
  • KINASE ANTAGONISTS
    申请人:KNIGHT ZACHARY A.
    公开号:US20100009963A1
    公开(公告)日:2010-01-14
    The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tyrosine kinase, PI3 kinase and mTOR, or PI33 kinase, mTOR and tyrosine kinase.
    本发明提供了一些新型化合物,它们是PI3激酶、PI3激酶和酪氨酸激酶、PI3激酶和mTOR、或PI3激酶、mTOR和酪氨酸激酶的拮抗剂。
  • KINASE INHIBITORS AND METHODS OF USE
    申请人:Liu Yi
    公开号:US20110077268A1
    公开(公告)日:2011-03-31
    The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating lipid kinases such PB kinases, tryosine kinases and protein kinases such as mTOR. Also provided in the present invention are methods of using these compositions to modulate these kinases especially for therapeutic applications.
    本发明提供了能够调节脂质激酶如PB激酶、酪氨酸激酶和蛋白激酶如mTOR的化学实体或化合物及其制药组合物。本发明还提供了使用这些组合物来调节这些激酶的方法,特别是用于治疗应用的方法。
查看更多